ArticleBreast cancer research : BCR2019

Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01).

Stefanie de Groot et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.